We therefore, tested the naked (unconjugated) commercially available ECD-binding GABRP-Ab that suppressed the growth of breast cancer cell lines, particularly MDA-MB-468, in a dose-dependent manner starting at 20 μg/ml. Here, GABRP is linked to breast carcinoma.